Table of Contents Table of Contents
Previous Page  297 / 812 Next Page
Information
Show Menu
Previous Page 297 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

S293

schizophrenia. Abs hydrolyzing DNA were detected in pool of poly-

clonal autoantibodies in autoimmune and infectious diseases, such

catalytic Abs were named abzymes.

Objectives

To investigate the level of anti-DNA antibodies and

DNA-hydrolyzing activity of IgG from the serum of patients with

schizophrenia depending on leading clinical symptoms.

Aims

– To measure the concentration of anti-DNA Abs in serum

of patients with leading positive and negative symptoms;

– to determine DNA-hydrolyzing activity of IgG.

Methods

In our study, 51 patients were included. The levels of

antiDNAAbswere determined using ELISA. DNA-hydrolyzing activ-

ity was detected as the level(%) of supercoiled pBluescript DNA

transition in circular and linear forms. Statistical analysis was per-

formed in “Statistica 9.0”.

Results

Anti-DNA Abs of patients with schizophrenia not only

bind DNA, but quite efficiently hydrolyze the substrate. IgG of

patient with schizophrenia were shown to possess DNA hydrolyz-

ing activity. It should be noted that DNAase activity of IgG in

patients with schizophrenia with a negative symptoms was signif-

icantly higher, than in patients with positive symptoms

( Table 1 ).

Conclusions

The data show a correlation with the level of DNase

activity and leading symptoms of patients with schizophrenia.

Table 1

Concentration of anti-DNA Abs and relative hydrolysis of

DNA in different groups of patients with schizophrenia.

Groups of patients Concentration of anti-DNA

Abs U/mL (M

±

SD)

Relative

hydrolysis

of DNA(%)

Anti-ssDNA Anti-dsDNA

Healthy donors

(

n

= 24)

7.4

±

2.7

6.9

±

0.9 9,1

±

6,5

Total group of

patients with

schizophrenia

(

n

= 51)

6.9

±

3.7

7.4

±

3.7 55.4

±

32.6*

Positive

symptoms

(

n

= 25)

7.2

±

4.1

5.3

±

3.05 43.3

±

33.1

Negative

symptoms

(

n

= 26)

5.4

±

2.4*

7.9

±

4.5 73.3

±

23.8**

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.628

EW511

Clinical and functional outcomes of

patients with severe schizophrenia

undergoing comprehensive

treatment: A 6-year follow-up

J.J. Fernandez-Miranda

, S. D

iaz-Fernandez

SESPA, AGCSM-V, Gijon, Spain

Corresponding author.

Introduction

To increase treatment compliance and conse-

quently to reach clinical and rehabilitation goals in people with

schizophrenia is a main challenge in their treatment.

Objectives and aims

To know the retention in treatment (and rea-

sons for discharge) of people with severe schizophrenia enrolled in

a specific, intensive, comprehensive and community programme

for them; and also to know treatment (clinical and functional) out-

comes.

Methods

A 6-year prospective, observational study of patients

with severe schizophrenia (ICD 10: F 20; CGI-S

5) undergoing

specific severe mental illness programme (

n

= 200). Assessment

included the Clinical Global Impression-Severity scale (CGI-S), the

Camberwell Assessment of Needs (CAN) and the WHO Disability

Assessment Schedule (WHO-DAS). Time in treatment and reasons

of discharge were measured. Laboratory tests, weight and medica-

tions were reported. Hospital admissions were measured.

Results

CGI at baseline was 5.86

±

0.7. After 6 years 48% of

patients continued under treatment (CGI = 4.31

±

0.8;

P

< 0.01);

31% were medical discharged (CGI = 3.62

±

1.6;

P

< 0.001); DAS

decreased in the four areas (

P

< 0.01) and also CAN (

P

< 0.01); 7% had

moved to other places; 8%were voluntary discharges. Eight patients

dead; three of them committed suicide. Forty-five percent of all of

them were treated with atypical long-acting antipsychotics, with

good tolerability. There were significantly less hospital admissions

than during the previous 6 years (

P

< 0.001).

Conclusions

Retention of severe mentally ill patients with

schizophrenia in a specific and intensive care programme was

really high; and seemed to help getting in remarkable clinical and

functional improvement. Long-acting medication also seemed to

be useful on improving treatment adherence, mainly due to their

good tolerability.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.629

EW512

Depressive symptoms in a sample of

patients diagnosed with

schizophrenia

A. Fernandez-Quintana

, M.D.C. García-Mahía

Clinical university hospital of La Coru˜na, psychiatry, La Coru˜na, Spain

Corresponding author.

Introduction

Previous studies highlight the difficulty of correctly

diagnosing depressive symptoms in schizophrenic patients, as well

as the impact on clinical progression among patients who present

with both syndromes, worsening treatment adherence and overall

prognosis.

Aims

To determine the prevalence of depressive symptoms in

patients diagnosed with schizophrenia. To analyze the relation-

ship of depressive symptoms with other demographic and clinical

variables.

Material and methods

Eighty-four patients diagnosed with

schizophrenia according to ICD-10 criteria and treated in an Outpa-

tient Mental Health Clinic were recruited for this study. Symptom

severity was assessed using The Positive and Negative Syndrome

Scale (PANSS; Kay et al., 1987); classifying patients as positive,

negative or mixed schizophrenia subtypes. Data from clinical and

sociodemographic variables was obtained from clinical records.

Results

The mean age was 43.2 years (SD: 10.2). Depression

is objectively detected in 10.3% of the sample, and presented as

subjective depression in 29.5%. The prevalence of depressive symp-

toms is higher among women, unmarried patients, lower social

classes and patients who met criteria for predominantly positive

Schizophrenia subtype. Higher prevalence of depressive symptoms

was found in patients with a shorter course of disease.

Conclusions

Depressive symptoms present with a high preva-

lence among patients diagnosed with schizophrenia, especially

during the early years of the disease. Given the severe impact of

depression on both the evolution and prognosis of patients with

severe mental illness, screening and early treatment must be car-

ried out.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.630